InMed Pharmaceuticals Inc.

As of June 30, 2026, InMed Pharmaceuticals Inc. carries a market capitalization of 7.32M, placing it among publicly traded companies globally. Its enterprise value stands at 5.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InMed Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, InMed Pharmaceuticals Inc. has 5.34M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.29, and the price-to-book ratio stands at 7.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.39M versus a market cap of 7.32M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, InMed Pharmaceuticals Inc. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -860.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, InMed Pharmaceuticals Inc. posted a negative return on equity (ROE) of -173.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -134.99, reflecting losses generated across the asset base. The company generates approximately 150,964.66 in revenue per employee across its workforce of 11.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, InMed Pharmaceuticals Inc.'s stock has declined approximately 32.02% over the past 52 weeks. The 50-day moving average sits at 1.21, while the 200-day moving average is 1.05.

Over the twelve months ended June 30, 2026, InMed Pharmaceuticals Inc. generated 1.70M in revenue and converted that into -10.99M in net income, yielding earnings per share of -2.44. EBITDA reached -8.06M, while operating income came in at -8.68M.

As of June 30, 2026, InMed Pharmaceuticals Inc. holds 1.92M in cash and equivalents against - - in total debt, resulting in a net debt position of -1.92M. Total book value stands at 940,953.63, with working capital of 631,656.74 providing operational flexibility.

InMed Pharmaceuticals Inc. produced -7.57M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -510.84 and net profit margin of -647.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -135.26: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.13, meaning InMed Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

InMed Pharmaceuticals Inc.'s most recent stock split took place on November 14, 2024 with a 20:1 split ratio.

As of June 30, 2026, InMed Pharmaceuticals Inc. has an Altman Z-Score of -67.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.